Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-11-10 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2020-11-10 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory context under the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) filing.
2020-11-10 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement detailing an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory context under the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) filing, as it describes a change in the company's capital structure due to the issuance of new shares.
2020-11-10 English
6-K
Foreign Filer Report
2020-11-05 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and details Genmab's decision to initiate a Phase 3 clinical study for its drug epcoritamab. It provides scientific background, study design details (GCT3013-05), and company boilerplate information. This type of announcement, which communicates a significant operational/clinical development milestone but is not a formal financial report (like 10-K or IR) or a transcript, typically falls under general regulatory announcements or investor relations material. Since it is a formal announcement of a clinical trial initiation, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general category for non-financial, operational news releases that are filed with regulators. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance document.
2020-11-05 English
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Regulatory Filings Classification · 95% confidence The document is a company announcement from Genmab regarding the initiation of a Phase 3 clinical trial for a drug candidate (epcoritamab). It provides details about the study, the disease, and the company's pipeline. While it contains significant information, it is structured as a press release/company announcement (indicated by 'Company Announcement no. 47' and the presence of an 'Attachment' link at the bottom). According to the 'Menu vs Meal' rule, since this is a short announcement that provides a link to an attached report, it is classified as a Report Publication Announcement.
2020-11-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.